Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies
G. Ralph Corey(Duke Medical Center), Paul Manos, Sinikka Green, Ivan Gudz, Н. А. Бубнова, Constantin Condrea, Chandrashekhar Mahakalkar(Jawaharlal Nehru Medical College), Roman S. Kozlov(Smolensk State Medical University), Abhijit Chandra, Marc D. Basson(Northeast Ohio Medical University), Michal Kazimir, James L. Chen(Mayo Clinic), Jorge Leiva, А. В. Конычев, Sandeep K. Gupta(M.V. Hospital and Research Centre), Firas Koura, Steven Mannis, David Leiman, Barry N. Heller, Greg Moeck(Doctors Company (United States)), Richard Keech, Matthew A. Wikler(Doctors Company (United States)), Robert O. Brennan, Christopher Lucasti, Heidi Kabler, P Altmeyer, Oscar DeValle, Maria del Rayo Morfin, Maria C. Laboranti, Clara Lombana-Martinez, Dipesh Duttarroy, Patrick Lee(Harvard University), Ashok Annadan Chandrasekharan, Borys G. Bezrodnyi, Dhananjay Kelkar, Julián González, Jeffery S. Loutit(Doctors Company (United States)), Osamah Hussein(Bar-Ilan University), Lala M. Dunbar, Donald R. Graham, William O’Riordan(Université Paris-Sud), Michael N. Dudley(Mapp Biopharmaceutical (United States)), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), Liudmila G. Lenskaya, Evgeniy Y. Levchik, Philip Giordano, Rajendra J. Lakhani, Luis Jáuregui-Peredo
Cited by 26
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
An Integrated Clinico-Metabolomic Model Improves Prediction of Death in Sepsis
|Science Translational Medicine|2013|512
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|509
Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed
|Archive ouverte UNIGE (University of Geneva)|2022|221
Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression
|Cancer Research|2017|199